Receptor-binding sites on C3 and C3b

The complement system plays a central role in innate immunity, yet the exact mechanisms governing C3 receptor interactions remain unclear. Prior research has shown that C3 and its cleavage products bind to cell surfaces, but the stability and accessibility of these binding sites are not fully understood. Some studies suggest that C3b and C3d receptors function differently depending on cell type and binding state. However, no prior work had resolved how receptor availability changes with C3b cleavage. This gap motivated further investigation into the structural dynamics of C3b binding. Understanding these interactions could clarify how immune responses are regulated at the cellular level. The complement system's role in immune signaling remains a key area of interest. The need to distinguish between stable and labile binding sites led to this study's focus.

This study aimed to investigate the binding properties of C3 and C3b on human erythrocytes and Daudi cells. The researchers wanted to determine whether these cells possess distinct receptor sites for C3b and C3d. By using two cell types with known receptor profiles, the team sought to clarify how receptor availability changes with C3b cleavage. The study's motivation stemmed from the need to understand how receptor binding is affected by structural changes in C3b. The researchers focused on identifying stable and labile binding sites on these cells. They also aimed to analyze how cleavage products influence receptor exposure. The goal was to provide insights into the dynamic interactions between complement proteins and cell surfaces. This approach could help distinguish between receptor-specific and structural effects.

The researchers used human erythrocytes and Daudi lymphoid cells as model systems. They isolated and cleaved human C3 to generate C3b and C3d. Binding experiments were conducted to assess receptor occupancy on both cell types. Fetal calf serum and a partially purified C3b-inactivator were used to induce cleavage of surface-bound C3b. Kinetic measurements tracked the accessibility of binding sites over time. The study focused on the transition of SBS2 from concealed to accessible states. Surface-bound C3b was analyzed for cleavage into C3c and C3d. The team monitored the delayed release of C3c to assess structural stability.

Freshly cleaved C3b binds via a labile site, concealing SBS2 on cell surfaces. Kinetic data show that SBS2 becomes accessible again after cleavage of surface-bound C3b. This reappearance coincides with the cleavage of C3b into C3c and C3d. However, C3c remains attached to the cell surface and is released only with delay. The number of SBS1 receptors decreases during cleavage events. This suggests that structural integrity of C3b is crucial for SBS1 expression. An alternative explanation is that SBS1 resides at the junction between C3c and C3d. Cleavage of this region may alter SBS1 availability.

The study suggests that C3b binding involves two distinct receptor sites on cell surfaces. The findings indicate that cleavage of C3b influences receptor accessibility dynamically. SBS2 becomes concealed upon initial binding but reappears after cleavage into C3c and C3d. The delayed release of C3c implies structural changes in surface-bound C3b. SBS1 availability appears to depend on the intact structure of C3b. The researchers propose that SBS1 may be located at the C3c-C3d junction. Cleavage of this region could alter receptor interactions. These results highlight the importance of structural integrity in C3b receptor binding.